Literature DB >> 14966565

Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism.

Takashi Shimada1, Makoto Kakitani, Yuji Yamazaki, Hisashi Hasegawa, Yasuhiro Takeuchi, Toshiro Fujita, Seiji Fukumoto, Kazuma Tomizuka, Takeyoshi Yamashita.   

Abstract

Inorganic phosphate is essential for ECM mineralization and also as a constituent of important molecules in cellular metabolism. Investigations of several hypophosphatemic diseases indicated that a hormone-like molecule probably regulates serum phosphate concentration. FGF23 has recently been recognized as playing important pathophysiological roles in several hypophosphatemic diseases. We present here the evidence that FGF23 is a physiological regulator of serum phosphate and 1,25-dihydroxyvitamin D (1,25[OH]2D) by generating FGF23-null mice. Disruption of the Fgf23 gene did not result in embryonic lethality, although homozygous mice showed severe growth retardation with abnormal bone phenotype and markedly short life span. The Fgf23(-/-) mice displayed significantly high serum phosphate with increased renal phosphate reabsorption. They also showed an elevation in serum 1,25(OH)2D that was due to the enhanced expression of renal 25-hydroxyvitamin D-1alpha-hydroxylase (1alpha-OHase) from 10 days of age. These phenotypes could not be explained by currently known regulators of mineral homeostasis, indicating that FGF23 is essential for normal phosphate and vitamin D metabolism.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14966565      PMCID: PMC338262          DOI: 10.1172/JCI19081

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  25 in total

1.  Deficient mineralization of intramembranous bone in vitamin D-24-hydroxylase-ablated mice is due to elevated 1,25-dihydroxyvitamin D and not to the absence of 24,25-dihydroxyvitamin D.

Authors:  R St-Arnaud; A Arabian; R Travers; F Barletta; M Raval-Pandya; K Chapin; J Depovere; C Mathieu; S Christakos; M B Demay; F H Glorieux
Journal:  Endocrinology       Date:  2000-07       Impact factor: 4.736

Review 2.  A molecular view of proximal tubular inorganic phosphate (Pi) reabsorption and of its regulation.

Authors:  H Murer; J Biber
Journal:  Pflugers Arch       Date:  1997-02       Impact factor: 3.657

3.  Targeted inactivation of Npt2 in mice leads to severe renal phosphate wasting, hypercalciuria, and skeletal abnormalities.

Authors:  L Beck; A C Karaplis; N Amizuka; A S Hewson; H Ozawa; H S Tenenhouse
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

Review 4.  PHEX gene and hypophosphatemia.

Authors:  M K Drezner
Journal:  Kidney Int       Date:  2000-01       Impact factor: 10.612

5.  25-Hydroxyvitamin D3 1alpha-hydroxylase and vitamin D synthesis.

Authors:  K Takeyama; S Kitanaka; T Sato; M Kobori; J Yanagisawa; S Kato
Journal:  Science       Date:  1997-09-19       Impact factor: 47.728

6.  Tumor-induced osteomalacia--unveiling a new hormone.

Authors:  M J Econs; M K Drezner
Journal:  N Engl J Med       Date:  1994-06-09       Impact factor: 91.245

Review 7.  Renal brush border membrane Na/Pi-cotransport: molecular aspects in PTH-dependent and dietary regulation.

Authors:  H Murer; M Lötscher; B Kaissling; M Levi; S A Kempson; J Biber
Journal:  Kidney Int       Date:  1996-06       Impact factor: 10.612

Review 8.  Vitamin D.

Authors:  A J Brown; A Dusso; E Slatopolsky
Journal:  Am J Physiol       Date:  1999-08

9.  Regulation of small intestinal Na-P(i) type IIb cotransporter by dietary phosphate intake.

Authors:  O Hattenhauer; M Traebert; H Murer; J Biber
Journal:  Am J Physiol       Date:  1999-10

10.  Bone histomorphometry in hypoparathyroid patients treated with vitamin D.

Authors:  B L Langdahl; L Mortensen; A Vesterby; E F Eriksen; P Charles
Journal:  Bone       Date:  1996-02       Impact factor: 4.398

View more
  554 in total

1.  Cholesterol in vascular and valvular calcification.

Authors:  L L Demer
Journal:  Circulation       Date:  2001-10-16       Impact factor: 29.690

Review 2.  Biology of Fibroblast Growth Factor 23: From Physiology to Pathology.

Authors:  Marie Courbebaisse; Beate Lanske
Journal:  Cold Spring Harb Perspect Med       Date:  2018-05-01       Impact factor: 6.915

3.  Salt causes aging-associated hypertension via vascular Wnt5a under Klotho deficiency.

Authors:  Wakako Kawarazaki; Risuke Mizuno; Mitsuhiro Nishimoto; Nobuhiro Ayuzawa; Daigoro Hirohama; Kohei Ueda; Fumiko Kawakami-Mori; Shigeyoshi Oba; Takeshi Marumo; Toshiro Fujita
Journal:  J Clin Invest       Date:  2020-08-03       Impact factor: 14.808

Review 4.  Miscellaneous non-inflammatory musculoskeletal conditions. Hyperphosphatemic familial tumoral calcinosis (FGF23, GALNT3 and αKlotho).

Authors:  Emily G Farrow; Erik A Imel; Kenneth E White
Journal:  Best Pract Res Clin Rheumatol       Date:  2011-10       Impact factor: 4.098

Review 5.  The role of vitamin D in the FGF23, klotho, and phosphate bone-kidney endocrine axis.

Authors:  Mark R Haussler; G Kerr Whitfield; Ichiro Kaneko; Ryan Forster; Rimpi Saini; Jui-Cheng Hsieh; Carol A Haussler; Peter W Jurutka
Journal:  Rev Endocr Metab Disord       Date:  2012-03       Impact factor: 6.514

Review 6.  Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism.

Authors:  L Darryl Quarles
Journal:  Nat Rev Endocrinol       Date:  2012-01-17       Impact factor: 43.330

7.  FGF23 beyond mineral metabolism: a bridge to cardiovascular disease.

Authors:  Tobias E Larsson
Journal:  Clin J Am Soc Nephrol       Date:  2011-12       Impact factor: 8.237

Review 8.  Klotho and aging.

Authors:  Makoto Kuro-o
Journal:  Biochim Biophys Acta       Date:  2009-02-20

9.  A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis.

Authors:  Shoji Ichikawa; Erik A Imel; Mary L Kreiter; Xijie Yu; Donald S Mackenzie; Andrea H Sorenson; Regina Goetz; Moosa Mohammadi; Kenneth E White; Michael J Econs
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

10.  Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice.

Authors:  Despina Sitara; Mohammed S Razzaque; Martina Hesse; Subbiah Yoganathan; Takashi Taguchi; Reinhold G Erben; Harald Jüppner; Beate Lanske
Journal:  Matrix Biol       Date:  2004-11       Impact factor: 11.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.